An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Colesevelam is an FDA-approved antihyperlipidemic drug. When treating hyperlipidemia, colesevelam should be used in conjunction with restriction of cholesterol and fat intake and exercise and can be used as a monotherapy or combined with an HMG-CoA reductase inhibitor ezetimibe, or niacin. It is approved for the treatment of hyperlipidemia from heterozygous familial hypercholesterolemia in adults and as well as in adolescents (10 to 17 years of age) patients. Colesevelam is also indicated to improve glycemic control in adults with type 2 diabetes mellitus along with diet and exercise.
Camilleri M, Acosta A, Busciglio I, Boldingh A, Dyer RB, Zinsmeister AR, Lueke A, Gray A, Donato LJ. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015 Mar;41(5):438-48.
-
PMC
-
PubMed
Nwose OM, Jones MR. Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes. 2013 Dec 08;6:75-9.
-
PMC
-
PubMed
Sonnett T, Robinson J, Milani P, Campbell RK. Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children. Adolesc Health Med Ther. 2010;1:53-60.
-
PMC
-
PubMed
Brunetti L, DeSantis EH. Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. P T. 2015 Jan;40(1):62-7.
-
PMC
-
PubMed
Zema MJ. Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evid. 2012;7:61-75.
-
PMC
-
PubMed
